CN105663208A - Drug combination for preventing and treating cirrhotic ascites and preparation method thereof - Google Patents

Drug combination for preventing and treating cirrhotic ascites and preparation method thereof Download PDF

Info

Publication number
CN105663208A
CN105663208A CN201610047129.7A CN201610047129A CN105663208A CN 105663208 A CN105663208 A CN 105663208A CN 201610047129 A CN201610047129 A CN 201610047129A CN 105663208 A CN105663208 A CN 105663208A
Authority
CN
China
Prior art keywords
weight portion
pharmaceutical composition
ethanol
percent concentration
weight
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
CN201610047129.7A
Other languages
Chinese (zh)
Inventor
不公告发明人
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jinan Xingyi Medical Technology Co Ltd
Original Assignee
Jinan Xingyi Medical Technology Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jinan Xingyi Medical Technology Co Ltd filed Critical Jinan Xingyi Medical Technology Co Ltd
Priority to CN201610047129.7A priority Critical patent/CN105663208A/en
Publication of CN105663208A publication Critical patent/CN105663208A/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/39—Convolvulaceae (Morning-glory family), e.g. bindweed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30—Extraction of the material
    • A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
    • A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30—Extraction of the material
    • A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/50—Methods involving additional extraction steps
    • A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/50—Methods involving additional extraction steps
    • A61K2236/55—Liquid-liquid separation; Phase separation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The invention discloses a drug combination for preventing and treating cirrhotic ascites and a preparation method thereof.The drug combination is prepared by proportioning Herba lagotis, Lysimachia hemsleyana, Sheareria nana, Peonidin, Andrographitis flavonoid glycoside C and Trifolirhizin which serve as active pharmaceutical ingredients, can be prepared into various dosage forms according to conventional preparation processes and has remarkable prevention and treatment effect on cirrhotic ascites.

Description

A kind of pharmaceutical composition preventing and treating cirrhotic ascites and preparation method thereof
Technical field
The invention belongs to technical field of Chinese medicines, particularly relate to a kind of pharmaceutical composition preventing and treating cirrhotic ascites and preparation method thereof.
Background technology
Cirrhotic ascites is to be controlled development formed by multiple chronic hepatopathy obstinate or delay mistake. Primary disease belongs to Chinese medicine " tympanites " category, and it is dirty that pathological changes relates generally to liver,spleen,kidney 3, and it is its important pathomechanism that depression of liver-QI, qi depression to blood stasis, insufficiency of the spleen mistake fortune, kidney yang are not changed. Liver controlling conveyance and dispersion, irritability is not dredged, disorder of QI movement, then three burnt water channels are obstructed, and accumulation forms ascites; The spleen has the function to transport and transform nutrients, and stagnation of liver-QI violates spleen, dysfunction of the spleen, and water is wet to stop gathering, and also becomes ascites; The kidney dominating water metabolism, built-in Yuanyang, the kidney usually involved in chronic disease, kidney yang virtual loss, to lose and evaporate, water gathers not all right, amasss in the part of the body cavity below the umbilicus, housing the bladder, kidneys and bowels, forms ascites. Though western medical treatment cirrhotic ascites has certain curative effect, but late result is not good enough, and relapse rate is high, and complication is many, and huge medical expense also makes patient hang back. The traditional Chinese medical science uses Chinese medicine from too many levels, Mutiple Targets on dialectical basis, treats cirrhotic ascites, and curative effect is certainly, safe, economical, has the unrivaled superiority of doctor trained in Western medicine. But, current Chinese medicine is observed mainly using the change of clinical symptoms and sign as the evaluation to therapeutic effect, and objectivity index study is less. Therefore in conjunction with modern Western medicine theory on differentiation of tcm basis, carry out treatment cirrhotic ascites herbal pharmacology research, face the card physical and chemical index in conjunction with microcosmic as the standard evaluating clinical efficacy, be the direction of Hepatocirrhosis in Chinese Herbal Medicine ascites research.
Rhizoma Calystegiae Hederaceae (Herba Calystegiae Hederaceae): this product is the herb of Convolvulaceae calystegia plant DAWANHUA CalystegiahederaceaWall. [Convolvu-lusjaponicusThunb.]. Summer, autumn gather, and clean, dry. [nature and flavor] sweet micro-hardship; Flat. [return through] liver; Kidney channel. [function cures mainly] spleen invigorating; Dampness removing; Regulating menstruation. Main weakness of the spleen and stomach; Dyspepsia; Infantile milk regurgitation; Infantile malnutrition; Five types of stranguria; Leukorrhagia; Menoxenia. [character] rhizome is elongated, and diameter is about 1mm, surface lark, has thin vertical wrinkle. Stem is elongated, normal tortuous turns round volume, surface taupe brown or taupe, has longitudinal crest line to distort; Matter is crisp, frangibility. Leaf alternate, has long handle, blade light green, and many shrinkages crush, and intact leaf is halberd shape after flattening. Feeble QI is lightly seasoned. [chemical analysis] rhizome is containing anti-caprolactone (columbin), palm leaf coculine (palmatine). Leaf lactoside containing Kaempferol-half (kaempferol-3-galacto-side). Record in Chinese medicine voluminous dictionary.
Lysimachia hemsleyana: this product is the herb of Primulaceae Lysimachia plant Lysimachia hemsleyana LysimachiahemsleyanaMaxim.. Summer gathers, and dries. [nature and flavor] micro-hardship; Cool in nature. [function cures mainly] clearing away heat-damp and promoting diuresis;Stimulate the menstrual flow. Main hepatitis; Pyelonephritis; Cystitis; Amenorrhea. Isolating potassium chloride and mixing saccharide in [chemical analysis] herb, preliminary examination still has the reactions such as flavonoid, Saponin, glycoside, lactone and organic acid. [pharmacological action] choleretic effect rat oral 100% Lysimachia hemsleyana decoct 5m1 every day, in continuous 6 weeks, in general anesthesia acute experiment situation, compares with matched group, has the effect promoting bile excretion. As relatively low in dosage or ophthalmically acceptable phase is short, then act on inconspicuous, continuous eye decoct is after 2-3 days, and animal feces is thinning, and color becomes sepia, but does not find intoxicating phenomenon. Rat is without gallbladder, therefore the excretion of promotion bile is not by strengthening caused by gallbladder contraction. Record in Chinese medicine voluminous dictionary.
Herba Sheareriae: this product is the herb of Compositae Herba Sheareriae platymiscium Herba Sheareriae SheareriananaS.Moore. Summer, autumn gather, magnesium with or dry. [nature and flavor] bitter in the mouth; Property is put down. [function cures mainly] heat-clearing and toxic substances removing; Inducing diuresis to remove edema. Main sore swollen toxin; Edema; Headache due to pathogenic wind-heat. [former phytomorph] annual herb. Stem is upright, high 30～40 centimetres, the following branch in middle part. Leaf alternate, sparse, linear, long 1～3 centimetre, wide 2～3 millimeters, tip point, base portion is narrow, Quan Yuan, stockless. Head inflorescence is little, and top is raw; Flower minority; Involucre is bell, bract 2 layers, and outer layer bract is extensively avette, and internal layer bract is slightly larger; Ligulate flower 3～4, white, female; Tubular flower 2～3, both sexes. Achene oblong. Florescence 8～JIUYUE. Record in Chinese medicine voluminous dictionary.
Peonidin (Peonidin): CAS 26838-13-1, molecular formula C22H23ClO11, molecular weight 498.87. [pharmacological action] antiinflammatory. [ingredient origin] Ericaceae Andromeda berry, during yak Er Miao section's Pelargonium and Paeoniaceae Paeonia are spent.
Andrographin glycosides C (AndrographidineC): CAS 113963-39-6, molecular formula C23H24O10, molecular weight 460.44. [ingredient origin] Herba Andrographis Andrographispaniculata [Syn.paniculata].
Trifolirhizin (Trifolirhizin): CAS 6807-83-6, molecular formula C22H22O10, molecular weight 446.40. [pharmacological action] has antibacterial action. The antitumaous effect of this product relatively other aglycons are strong, but more weak than its dextrorotation. [ingredient origin] Herba Trifolii Pratentis Trifoliumpratense, Radix Sophorae Tonkinensis Sophorasubprostrata ［ Syn.Sophoratonkinensis ］.
The chemical constitution of 3 crude drug:
Andrographin glycosides C (AndrographidineC)
Peonidin (Peonidin) trifolirhizin (Trifolirhizin).
Summary of the invention
It is an object of the invention to overcome the deficiency of background technology, it is provided that a kind of effectively pharmaceutical composition preventing and treating cirrhotic ascites and preparation method thereof.
The present invention adopts the following technical scheme that realization:
Composition and the weight portion of making the crude drug of this pharmaceutical composition preventing and treating cirrhotic ascites be:
Rhizoma Calystegiae Hederaceae (Herba Calystegiae Hederaceae) 3050-3090 weight portion Lysimachia hemsleyana 35-45 weight portion Herba Sheareriae 2608-2708 weight portion peonidin 130-145 weight portion andrographin glycosides C96-98 weight portion trifolirhizin 60-68 weight portion.
It is preferably used in the pharmaceutical composition preventing and treating cirrhotic ascites, is prepared by the crude drug composition of weight portion:
Rhizoma Calystegiae Hederaceae (Herba Calystegiae Hederaceae) 3070 weight portion Lysimachia hemsleyana 40 weight portion Herba Sheareriae 2658 weight portion peonidin 140 weight portion andrographin glycosides C97 weight portion trifolirhizin 64 weight portion.
A kind of pharmaceutical composition preventing and treating cirrhotic ascites, it is characterised in that pharmaceutical composition can adopt the conventional method of galenic pharmacy to prepare into tablet or capsule or drop pill.
A kind of pharmaceutical composition preventing and treating cirrhotic ascites, it is characterised in that what pharmaceutical composition and chemical drugs or Chinese medicine formed prevents and treats cirrhotic ascites medicine.
The preparation method of a kind of pharmaceutical composition preventing and treating cirrhotic ascites, it is characterised in that prepare as follows:
The composition of crude drug and weight portion be: Rhizoma Calystegiae Hederaceae (Herba Calystegiae Hederaceae) 3050-3090 weight portion Lysimachia hemsleyana 35-45 weight portion Herba Sheareriae 2608-2708 weight portion peonidin 130-145 weight portion andrographin glycosides C96-98 weight portion trifolirhizin 60-68 weight portion;
Preparation method:
(1) Lysimachia hemsleyana is taken by crude drug proportioning, Herba Sheareriae, Rhizoma Calystegiae Hederaceae (Herba Calystegiae Hederaceae), peonidin, andrographin glycosides C, trifolirhizin, mixing, with weight percent concentration 11% ethanol as solvent, extract at 29 DEG C of warm macerating, extraction time is 6 times, each extraction time is 38 hours, each solvent load is 41.5 times of crude drug gross weight, filter, obtain medicinal residues A and extracting solution A, extracting solution A reclaims ethanol, it is concentrated into relative density 1.17, filter, medicinal liquid passes through LSA-40 macroporous adsorptive resins, first wash with water, again with weight percent concentration 84% alcoholic solution eluting LSA-40 macroporous adsorptive resins, collect weight percent concentration 84% ethanol elution, reclaim ethanol, concentrate drying, obtain extract A,
(2) step (1) medicinal residues A is taken, with weight percent concentration 47% ethanol as solvent, heating and refluxing extraction 20 times, each extraction time is 0.2 hour, each solvent load is 7 times of medicinal residues A weight, filter, obtain medicinal residues B and extracting solution B, extracting solution B reclaims ethanol, it is concentrated into relative density 1.16, filter, medicinal liquid passes through LKS03 macroporous adsorptive resins, first wash with water, again with weight percent concentration 69% alcoholic solution eluting LKS03 macroporous adsorptive resins, collect weight percent concentration 69% ethanol elution, reclaim ethanol, concentrate drying, obtain extract B,
(3) extract A and extract B are mixed, obtain pharmaceutical composition.
The preferably preparation method of a kind of pharmaceutical composition preventing and treating cirrhotic ascites, it is characterised in that prepare as follows:
The composition of crude drug and weight portion be: Rhizoma Calystegiae Hederaceae (Herba Calystegiae Hederaceae) 3070 weight portion Lysimachia hemsleyana 40 weight portion Herba Sheareriae 2658 weight portion peonidin 140 weight portion andrographin glycosides C97 weight portion trifolirhizin 64 weight portion;
Preparation method:
(1) Lysimachia hemsleyana is taken by crude drug proportioning, Herba Sheareriae, Rhizoma Calystegiae Hederaceae (Herba Calystegiae Hederaceae), peonidin, andrographin glycosides C, trifolirhizin, mixing, with weight percent concentration 11% ethanol as solvent, extract at 29 DEG C of warm macerating, extraction time is 6 times, each extraction time is 38 hours, each solvent load is 41.5 times of crude drug gross weight, filter, obtain medicinal residues A and extracting solution A, extracting solution A reclaims ethanol, it is concentrated into relative density 1.17, filter, medicinal liquid passes through LSA-40 macroporous adsorptive resins, first wash with water, again with weight percent concentration 84% alcoholic solution eluting LSA-40 macroporous adsorptive resins, collect weight percent concentration 84% ethanol elution, reclaim ethanol, concentrate drying, obtain extract A,
(2) step (1) medicinal residues A is taken, with weight percent concentration 47% ethanol as solvent, heating and refluxing extraction 20 times, each extraction time is 0.2 hour, each solvent load is 7 times of medicinal residues A weight, filter, obtain medicinal residues B and extracting solution B, extracting solution B reclaims ethanol, it is concentrated into relative density 1.16, filter, medicinal liquid passes through LKS03 macroporous adsorptive resins, first wash with water, again with weight percent concentration 69% alcoholic solution eluting LKS03 macroporous adsorptive resins, collect weight percent concentration 69% ethanol elution, reclaim ethanol, concentrate drying, obtain extract B,
(3) extract A and extract B are mixed, obtain pharmaceutical composition.
The preparation method of a kind of pharmaceutical composition preventing and treating cirrhotic ascites, it is characterised in that pharmaceutical composition can adopt the conventional method of galenic pharmacy to prepare into tablet or capsule or drop pill.
The preparation method of a kind of pharmaceutical composition preventing and treating cirrhotic ascites, it is characterised in that pharmaceutical composition prevents and treats cirrhotic ascites medicine with chemical drugs or Chinese medicine composition.
It is notable that pharmaceutical composition prevents and treats cirrhotic ascites effect.
Detailed description of the invention
Embodiment 1: pharmaceutical composition preventing and treating cirrhotic ascites and preparation method thereof
Composition and the weight portion of preventing and treating the crude drug of the pharmaceutical composition of cirrhotic ascites be: Rhizoma Calystegiae Hederaceae (Herba Calystegiae Hederaceae) 3070g Lysimachia hemsleyana 40g Herba Sheareriae 2658g peonidin 140g andrographin glycosides C97g trifolirhizin 64g;
Preparation method:
(1) Lysimachia hemsleyana is taken by crude drug proportioning, Herba Sheareriae, Rhizoma Calystegiae Hederaceae (Herba Calystegiae Hederaceae), peonidin, andrographin glycosides C, trifolirhizin, mixing, with weight percent concentration 11% ethanol as solvent, extract at 29 DEG C of warm macerating, extraction time is 6 times, each extraction time is 38 hours, each solvent load is 41.5 times of crude drug gross weight, filter, obtain medicinal residues A and extracting solution A, extracting solution A reclaims ethanol, it is concentrated into relative density 1.17, filter, medicinal liquid passes through LSA-40 macroporous adsorptive resins, first wash with water, again with weight percent concentration 84% alcoholic solution eluting LSA-40 macroporous adsorptive resins, collect weight percent concentration 84% ethanol elution, reclaim ethanol, concentrate drying, obtain extract A,
(2) step (1) medicinal residues A is taken, with weight percent concentration 47% ethanol as solvent, heating and refluxing extraction 20 times, each extraction time is 0.2 hour, each solvent load is 7 times of medicinal residues A weight, filter, obtain medicinal residues B and extracting solution B, extracting solution B reclaims ethanol, it is concentrated into relative density 1.16, filter, medicinal liquid passes through LKS03 macroporous adsorptive resins, first wash with water, again with weight percent concentration 69% alcoholic solution eluting LKS03 macroporous adsorptive resins, collect weight percent concentration 69% ethanol elution, reclaim ethanol, concentrate drying, obtain extract B,
(3) extract A and extract B are mixed, obtain pharmaceutical composition.
Embodiment 2: pharmaceutical composition preventing and treating cirrhotic ascites and preparation method thereof
Composition and the weight portion of preventing and treating the crude drug of the pharmaceutical composition of cirrhotic ascites be: Rhizoma Calystegiae Hederaceae (Herba Calystegiae Hederaceae) 3050g Lysimachia hemsleyana 45g Herba Sheareriae 2608g peonidin 145g andrographin glycosides C96g trifolirhizin 68g;
Preparation method:
(1) Lysimachia hemsleyana is taken by crude drug proportioning, Herba Sheareriae, Rhizoma Calystegiae Hederaceae (Herba Calystegiae Hederaceae), peonidin, andrographin glycosides C, trifolirhizin, mixing, with weight percent concentration 11% ethanol as solvent, extract at 29 DEG C of warm macerating, extraction time is 6 times, each extraction time is 38 hours, each solvent load is 41.5 times of crude drug gross weight, filter, obtain medicinal residues A and extracting solution A, extracting solution A reclaims ethanol, it is concentrated into relative density 1.17, filter, medicinal liquid passes through LSA-40 macroporous adsorptive resins, first wash with water, again with weight percent concentration 84% alcoholic solution eluting LSA-40 macroporous adsorptive resins, collect weight percent concentration 84% ethanol elution, reclaim ethanol, concentrate drying, obtain extract A,
(2) step (1) medicinal residues A is taken, with weight percent concentration 47% ethanol as solvent, heating and refluxing extraction 20 times, each extraction time is 0.2 hour, each solvent load is 7 times of medicinal residues A weight, filter, obtain medicinal residues B and extracting solution B, extracting solution B reclaims ethanol, it is concentrated into relative density 1.16, filter, medicinal liquid passes through LKS03 macroporous adsorptive resins, first wash with water, again with weight percent concentration 69% alcoholic solution eluting LKS03 macroporous adsorptive resins, collect weight percent concentration 69% ethanol elution, reclaim ethanol, concentrate drying, obtain extract B,
(3) extract A and extract B are mixed, obtain pharmaceutical composition.
Embodiment 3: pharmaceutical composition preventing and treating cirrhotic ascites and preparation method thereof
Composition and the weight portion of preventing and treating the crude drug of the pharmaceutical composition of cirrhotic ascites be: Rhizoma Calystegiae Hederaceae (Herba Calystegiae Hederaceae) 3090g Lysimachia hemsleyana 35g Herba Sheareriae 2708g peonidin 130g andrographin glycosides C98g trifolirhizin 60g;
Preparation method:
(1) Lysimachia hemsleyana is taken by crude drug proportioning, Herba Sheareriae, Rhizoma Calystegiae Hederaceae (Herba Calystegiae Hederaceae), peonidin, andrographin glycosides C, trifolirhizin, mixing, with weight percent concentration 11% ethanol as solvent, extract at 29 DEG C of warm macerating, extraction time is 6 times, each extraction time is 38 hours, each solvent load is 41.5 times of crude drug gross weight, filter, obtain medicinal residues A and extracting solution A, extracting solution A reclaims ethanol, it is concentrated into relative density 1.17, filter, medicinal liquid passes through LSA-40 macroporous adsorptive resins, first wash with water, again with weight percent concentration 84% alcoholic solution eluting LSA-40 macroporous adsorptive resins, collect weight percent concentration 84% ethanol elution, reclaim ethanol, concentrate drying, obtain extract A,
(2) step (1) medicinal residues A is taken, with weight percent concentration 47% ethanol as solvent, heating and refluxing extraction 20 times, each extraction time is 0.2 hour, each solvent load is 7 times of medicinal residues A weight, filter, obtain medicinal residues B and extracting solution B, extracting solution B reclaims ethanol, it is concentrated into relative density 1.16, filter, medicinal liquid passes through LKS03 macroporous adsorptive resins, first wash with water, again with weight percent concentration 69% alcoholic solution eluting LKS03 macroporous adsorptive resins, collect weight percent concentration 69% ethanol elution, reclaim ethanol, concentrate drying, obtain extract B,
(3) extract A and extract B are mixed, obtain pharmaceutical composition.
Embodiment 4: the preparation of tablet
Example 1 pharmaceutical composition 349g, adds starch 167g, mixing, granulates, dry, adds microcrystalline Cellulose 66g, magnesium stearate 4g, and mixing is pressed into 1500, obtains medicinal composition tablets.
Embodiment 5: the preparation of capsule
Example 2 pharmaceutical composition 379g, adds starch 125g, mixing, granulates, dry, and granulate adds appropriate magnesium stearate, mixing, encapsulated 1500, obtains medicament composition capsule.
Embodiment 6: the preparation of drop pill
Weigh polyethylene glycol 6000 398g water-bath (80 DEG C) heating and boil molten, add embodiment 3 pharmaceutical composition 22g, stir, with liquid paraffin for coolant, put in glass tubing (4*80cm), chilling temperature is 7 DEG C, drip internal-and external diameter is 7.0/2.0 (mm/mm), and drip is 2.1cm from liquid level, drips speed with per minute 67 for optimum condition, blot the condensing agent on drop pill surface with cotton, obtain medicament composition dropping pills.
Embodiment 7: prevent and treat the pharmaceutical composition of cirrhotic ascites
Composition and the weight portion of preventing and treating the crude drug of the pharmaceutical composition of cirrhotic ascites be:
Rhizoma Calystegiae Hederaceae (Herba Calystegiae Hederaceae) 2850 weight portion peonidin 130 weight portion andrographin glycosides C48 weight portion trifolirhizin 60 weight portion.
Embodiment 8: prevent and treat the pharmaceutical composition of cirrhotic ascites
Composition and the weight portion of preventing and treating the crude drug of the pharmaceutical composition of cirrhotic ascites be:
Rhizoma Calystegiae Hederaceae (Herba Calystegiae Hederaceae) 3500 weight portion peonidin 110 weight portion andrographin glycosides C100 weight portion trifolirhizin 45 weight portion.
Embodiment 9: prevent and treat the pharmaceutical composition of cirrhotic ascites
Composition and the weight portion of preventing and treating the crude drug of the pharmaceutical composition of cirrhotic ascites be:
Rhizoma Calystegiae Hederaceae (Herba Calystegiae Hederaceae) 3000 weight portion peonidin 150 weight portion andrographin glycosides C88 weight portion trifolirhizin 30 weight portion.
Experimental example 1: prevent and treat the experimental study of cirrhotic ascites
1 physical data
Select to be in hospital and outpatient service patients with cirrhosis ascites 48 example, be randomly divided into treatment group and matched group. Treatment group 24 example, male 12 examples, female 12 example; 31～69 years old age, average (50.6 ± 10.6) year; The course of disease 6 months～9 years, average (5.22 ± 1.35) year; 1st time ascites person 9 example occurs, the 2nd time ascites person 8 example occurs, the 3rd time and appear above ascites person 7 example, a small amount of ascites person 7 example, middle amount ascites person 8 example, a large amount of ascites person 9 examples; Ascites person 17 example, alcoholic liver ascites person 3 example, other 4 examples occur after hepatitis; Concurrent hydrothorax person 1 example, hepatic coma person 1 example, slight upper gastrointestinal hemorrhage person 2 example. Matched group 24 example, male 12 examples, female 12 example; 31～69 years old age, average (50.7 ± 10.8) year; The course of disease 6 months～9 years, average (5.38 ± 1.36) year; 1st time ascites person 9 example occurs, the 2nd time ascites person 8 example occurs, the 3rd time and appear above ascites person 7 example, a small amount of ascites person 7 example, middle amount ascites person 8 example, a large amount of ascites person 9 examples; Ascites person 17 example, alcoholic liver ascites person 3 example, other 4 examples occur after hepatitis; Concurrent hydrothorax person 1 example, hepatic coma person 1 example, slight upper gastrointestinal hemorrhage person 2 example. Two groups of patient's physical data contrasts, difference not statistically significant (P > 0.05), there is comparability.
2 test case standards
According to " viral hepatitis control prece " standard, and confirm there is ascites through ultrasound diagnosis. Get rid of carcinous, Tuberculous or the ascites of other reasons appearance. Patient has chest and abdomen swelling and pain, umbilicus abdomen to swell more, and feelings will is not relaxed, ochriasis, poor appetite of feeling sick, the symptoms such as lower limbs edema, corpulent tongue are big, deep pulse is moistened.
3 Therapeutic Method
Matched group adopts composite treatment: 1. low salt diet. 2. hydrochlorothiazide 50mg, every day 2 times, oral; Spironolactone 40mg, every day 2 times, oral. 3. liver protecting therapy. 4. take the circumstances into consideration to use human albumin, branched-chain amino acid. 5. electrolyte disturbance is corrected, it is prevented that complication.
Treatment group adds pharmaceutical composition treatment (embodiment 1 pharmaceutical composition lot number 20110811), each 1g, every day 3 times on treatment of control group basis.
Two groups, all with 1 month for 1 course for the treatment of, judge curative effect after 2 courses for the treatment of.
4 curative effect determinate standards
With reference to " new Chinese medicine guideline of clinical investigations " standard. Effective: clinical symptom disappearance, ascites is known and is removed, and hepatosplenomegaly reduces or stablizes constant, and liver function recovery is normal. Effective: cardinal symptom disappears or is obviously improved, ascites reduces, and hepatosplenomegaly is stablized constant, and liver function index is decreased obviously. It is invalid: even the state of an illness changes inconspicuous or increases the weight of without changing.
5 results
5.1 liang of group Comparison of therapeutic
In Table 1.
1 liang of table group Comparison of therapeutic
Group Number of cases Effective Effectively Invalid Effective percentage/%
Treatment group 24 10 12 2 91.67
Matched group 24 7 10 7 70.83
Two groups of contrasts, treatment group curative effect is substantially better than matched group, difference statistically significant (P < 0.05).
5.2 follow up a case by regular visits to
Following up a case by regular visits to after half a year, in treatment group 22 examples effective, effective, ascites recurs or adds severe one 4 example, relapse rate 18.18%; In matched group 17 examples effective, effective, ascites recurs or adds severe one 5 example, relapse rate 29.41%.

Claims (8)

1. the pharmaceutical composition preventing and treating cirrhotic ascites, it is characterised in that composition and the weight portion of making the crude drug of this pharmaceutical composition be:
Rhizoma Calystegiae Hederaceae (Herba Calystegiae Hederaceae) 3050-3090 weight portion Lysimachia hemsleyana 35-45 weight portion Herba Sheareriae 2608-2708 weight portion peonidin 130-145 weight portion andrographin glycosides C96-98 weight portion trifolirhizin 60-68 weight portion.
2. a kind of pharmaceutical composition preventing and treating cirrhotic ascites according to claim 1, it is characterised in that composition and the weight portion of making the crude drug of this pharmaceutical composition be:
Rhizoma Calystegiae Hederaceae (Herba Calystegiae Hederaceae) 3070 weight portion Lysimachia hemsleyana 40 weight portion Herba Sheareriae 2658 weight portion peonidin 140 weight portion andrographin glycosides C97 weight portion trifolirhizin 64 weight portion.
3. a kind of pharmaceutical composition preventing and treating cirrhotic ascites according to claim 1, it is characterised in that pharmaceutical composition can adopt the conventional method of galenic pharmacy to prepare into tablet or capsule or drop pill.
4. a kind of pharmaceutical composition preventing and treating cirrhotic ascites according to claim 1, it is characterised in that pharmaceutical composition and chemical drugs or Chinese medicine composition prevent and treat cirrhotic ascites medicine.
5. the preparation method of the pharmaceutical composition preventing and treating cirrhotic ascites, it is characterised in that prepare as follows:
The composition of crude drug and weight portion be: Rhizoma Calystegiae Hederaceae (Herba Calystegiae Hederaceae) 3050-3090 weight portion Lysimachia hemsleyana 35-45 weight portion Herba Sheareriae 2608-2708 weight portion peonidin 130-145 weight portion andrographin glycosides C96-98 weight portion trifolirhizin 60-68 weight portion;
Preparation method:
(1) Lysimachia hemsleyana is taken by crude drug proportioning, Herba Sheareriae, Rhizoma Calystegiae Hederaceae (Herba Calystegiae Hederaceae), peonidin, andrographin glycosides C, trifolirhizin, mixing, with weight percent concentration 11% ethanol as solvent, extract at 29 DEG C of warm macerating, extraction time is 6 times, each extraction time is 38 hours, each solvent load is 41.5 times of crude drug gross weight, filter, obtain medicinal residues A and extracting solution A, extracting solution A reclaims ethanol, it is concentrated into relative density 1.17, filter, medicinal liquid passes through LSA-40 macroporous adsorptive resins, first wash with water, again with weight percent concentration 84% alcoholic solution eluting LSA-40 macroporous adsorptive resins, collect weight percent concentration 84% ethanol elution, reclaim ethanol, concentrate drying, obtain extract A,
(2) step (1) medicinal residues A is taken, with weight percent concentration 47% ethanol as solvent, heating and refluxing extraction 20 times, each extraction time is 0.2 hour, each solvent load is 7 times of medicinal residues A weight, filter, obtain medicinal residues B and extracting solution B, extracting solution B reclaims ethanol, it is concentrated into relative density 1.16, filter, medicinal liquid passes through LKS03 macroporous adsorptive resins, first wash with water, again with weight percent concentration 69% alcoholic solution eluting LKS03 macroporous adsorptive resins, collect weight percent concentration 69% ethanol elution, reclaim ethanol, concentrate drying, obtain extract B,
(3) extract A and extract B are mixed, obtain pharmaceutical composition.
6. the preparation method of a kind of pharmaceutical composition preventing and treating cirrhotic ascites according to claim 5, it is characterised in that prepare as follows:
The composition of crude drug and weight portion be: Rhizoma Calystegiae Hederaceae (Herba Calystegiae Hederaceae) 3070 weight portion Lysimachia hemsleyana 40 weight portion Herba Sheareriae 2658 weight portion peonidin 140 weight portion andrographin glycosides C97 weight portion trifolirhizin 64 weight portion;
Preparation method:
(1) Lysimachia hemsleyana is taken by crude drug proportioning, Herba Sheareriae, Rhizoma Calystegiae Hederaceae (Herba Calystegiae Hederaceae), peonidin, andrographin glycosides C, trifolirhizin, mixing, with weight percent concentration 11% ethanol as solvent, extract at 29 DEG C of warm macerating, extraction time is 6 times, each extraction time is 38 hours, each solvent load is 41.5 times of crude drug gross weight, filter, obtain medicinal residues A and extracting solution A, extracting solution A reclaims ethanol, it is concentrated into relative density 1.17, filter, medicinal liquid passes through LSA-40 macroporous adsorptive resins, first wash with water, again with weight percent concentration 84% alcoholic solution eluting LSA-40 macroporous adsorptive resins, collect weight percent concentration 84% ethanol elution, reclaim ethanol, concentrate drying, obtain extract A,
(2) step (1) medicinal residues A is taken, with weight percent concentration 47% ethanol as solvent, heating and refluxing extraction 20 times, each extraction time is 0.2 hour, each solvent load is 7 times of medicinal residues A weight, filter, obtain medicinal residues B and extracting solution B, extracting solution B reclaims ethanol, it is concentrated into relative density 1.16, filter, medicinal liquid passes through LKS03 macroporous adsorptive resins, first wash with water, again with weight percent concentration 69% alcoholic solution eluting LKS03 macroporous adsorptive resins, collect weight percent concentration 69% ethanol elution, reclaim ethanol, concentrate drying, obtain extract B,
(3) extract A and extract B are mixed, obtain pharmaceutical composition.
7. the preparation method of a kind of pharmaceutical composition preventing and treating cirrhotic ascites according to claim 5, it is characterised in that pharmaceutical composition can adopt the conventional method of galenic pharmacy to prepare into tablet or capsule or drop pill.
8. the preparation method of a kind of pharmaceutical composition preventing and treating cirrhotic ascites according to claim 5, it is characterised in that pharmaceutical composition prevents and treats cirrhotic ascites medicine with chemical drugs or Chinese medicine composition.
CN201610047129.7A 2016-01-25 2016-01-25 Drug combination for preventing and treating cirrhotic ascites and preparation method thereof Withdrawn CN105663208A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201610047129.7A CN105663208A (en) 2016-01-25 2016-01-25 Drug combination for preventing and treating cirrhotic ascites and preparation method thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201610047129.7A CN105663208A (en) 2016-01-25 2016-01-25 Drug combination for preventing and treating cirrhotic ascites and preparation method thereof

Publications (1)

Publication Number Publication Date
CN105663208A true CN105663208A (en) 2016-06-15

Family

ID=56302328

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201610047129.7A Withdrawn CN105663208A (en) 2016-01-25 2016-01-25 Drug combination for preventing and treating cirrhotic ascites and preparation method thereof

Country Status (1)

Country Link
CN (1) CN105663208A (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106852946A (en) * 2016-12-10 2017-06-16 济南昊雨青田医药技术有限公司 A kind of pharmaceutical composition for treating laryngitis

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106852946A (en) * 2016-12-10 2017-06-16 济南昊雨青田医药技术有限公司 A kind of pharmaceutical composition for treating laryngitis

Similar Documents

Publication Publication Date Title
CN105343625A (en) Taraxacum oral liquid for expelling toxin, dehumidifying and benefiting gallbladder and preparation method thereof
CN103520593B (en) Chinese herba preparation for treating trichomonas vaginitis and preparation method thereof
CN103610795B (en) A kind of preparation method of eucommia bark depressor oral formulations
CN110538281A (en) traditional Chinese medicine preparation for treating pharyngitis and tonsillitis, preparation method and application
CN103191167B (en) Application of eupatorium Chinese
CN105663208A (en) Drug combination for preventing and treating cirrhotic ascites and preparation method thereof
CN103735695A (en) Chinese medicine composition for treating urinary tract infection and preparation method thereof
CN103550528B (en) Chinese herbal preparation for treating stomach-Yin deficient chronic gastritis and preparation method thereof
CN103520575B (en) A kind of Chinese medicine preparation and preparation method for the treatment of spleen and stomach damp-heat type chronic gastritis
CN103386101B (en) Traditional Chinese medicine preparation for nonspecific cystitis treatment and preparation method thereof
CN105362602A (en) Traditional Chinese medicine preparation for treating dysfunctional uterine bleeding and preparation method of traditional Chinese medicine preparation for treating dysfunctional uterine bleeding
CN104013815A (en) Traditional Chinese medicine for treating recurrent oral ulcer due to deficiency of yin and excess of heat and preparation method of traditional Chinese medicine
CN103520620B (en) A kind of Chinese medicine preparation and preparation method for the treatment of due to weakness of spleen and stomach chronic gastritis
CN103705692B (en) A kind of Chinese medicine preparation for the treatment of acute gastroenteritis
CN103285161A (en) Anti-virus traditional Chinese medicinal composition and preparation method thereof
CN106109927A (en) A kind of pharmaceutical composition treating chloasma and preparation method thereof
CN105168397A (en) Medicine composition for preventing and treating nephrosis
CN104707124A (en) Traditional Chinese medicine preparation for treating chronic endometritis
CN104524460A (en) Pharmaceutical composition for preventing and treating acute nephritis and application thereof
CN104815267A (en) Traditional Chinese medicine preparation capable of promoting digestion and relieving stasis to treat infantile indigestion with food retention
CN104524149A (en) Pharmaceutical composition for preventing and treating acute nephritis and application thereof
CN103860939A (en) Medicament containing camellia bud extract and used for treating epistaxis and preparation method thereof
CN104623471A (en) Traditional Chinese medicine emulsion for treating stomach and duodenal ulcer and preparation method thereof
CN104740313B (en) One kind treats chronic gastritis Chinese medicine composition and preparation method thereof
CN104587078A (en) Traditional Chinese medicine preparation for treating viral pharyngitis

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
WW01 Invention patent application withdrawn after publication
WW01 Invention patent application withdrawn after publication

Application publication date: 20160615